Vaccine research has long relied on rodents as models for understanding human immune response. Although such models are often useful as a first step in vaccine development, there is increasing evidence that the rodent immune system is markedly different from humans, and that primate model platforms are a more accurate early stage surrogate for human subjects. Preclinical Translational Services offers ready access to several species of well-characterized nonhuman primates, thereby providing an efficient, fast-track approach to vaccine innovation and development.
Because of their many similarities to people, primate models can be more efficient and accurate in providing a one-step, “development to application” strategy for vaccine innovation research. Such an approach can reduce the number of animals needed for studies of efficacy. This one-step strategy is a powerful validation approach that minimizes expenditures by reducing both the time and the number of total animal subjects often required when using rodent models.
Models Available for Testing Vaccine Innovations
- Specific pathogen free (SPF) cynomolgus macaques (Macaca fascicularis)
- Rhesus monkeys (M. mulatta)
- Pedigreed and genomically sequenced African green monkeys (vervets, Chlorocebus aethiops)